MedTrace Logo

Evaluation of the AIVARIX in Detecting Signs C 1-2 Classes of CVD

NCT05612217 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 433

Last updated 2024-09-25

Study results available
· View outcomes & findings →

Summary

This study is a multicenter observational study, which is carried out in frame of routine clinical practice in Russia. The program will include patients suggestive to chronic venous diseases (CVDs) including but not limited to those with C1 and C2 classes by CEAP classification, who will be seeking professional phlebologists' consultation. Study conduction is scheduled in Russia in 2022-2023. The planned number of patients is 414

Conditions

  • Chronic Venous Disease
  • CVD

Interventions

OTHER

to estimate Sensitivity and Specificity AIVARIX app in detecting C1 and C2 classes of CVD

to estimate Sensitivity and Specificity of the AI-based AIVARIX app in detecting C1 and C2 classes of CVD in patients who are seeking for professional advice from a phlebologist regarding symptoms and signs suggestive to CVD.

Sponsors & Collaborators

  • Servier Russia

    lead INDUSTRY

Principal Investigators

  • IGOR ZOLOTUKHIN · Pirogov Russian National Research Medical University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-01
Primary Completion
2023-06-01
Completion
2024-04-01

Countries

  • Russia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05612217 on ClinicalTrials.gov